Thalidomide Patent Expiration
Thalidomide is Used for treating multiple myeloma and erythema nodosum leprosum. It was first introduced by Bristol-Myers Squibb Co
Thalidomide Patents
Given below is the list of patents protecting Thalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Thalomid | US7230012 | Pharmaceutical compositions and dosage forms of thalidomide |
Dec 09, 2023
(Expired) | Bristol-myers |
| Thalomid | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6869399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7141018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7959566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7874984 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7435745 | Methods and compositions for inhibition of angiogenesis |
Nov 03, 2017
(Expired) | Bristol-myers |
| Thalomid | US5629327 | Methods and compositions for inhibition of angiogenesis |
May 13, 2014
(Expired) | Bristol-myers |
| Thalomid | US6235756 | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US7723361 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US8143283 | Methods for treating blood-born tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Thalidomide's patents.
Latest Legal Activities on Thalidomide's Patents
Given below is the list recent legal activities going on the following patents of Thalidomide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 17 Jul, 2023 | US7959566 |
| Expire Patent Critical
| 27 Feb, 2023 | US7874984 |
| Maintenance Fee Reminder Mailed Critical
| 30 Jan, 2023 | US7959566 |
| Maintenance Fee Reminder Mailed Critical
| 12 Sep, 2022 | US7874984 |
| Expire Patent Critical
| 16 Nov, 2020 | US7435745(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 01 Jun, 2020 | US7435745(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Dec, 2018 | US7959566 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Dec, 2018 | US7230012(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jul, 2018 | US7874984 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2018 | US7141018 |
Thalidomide's Family Patents
